for people ages 12 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Tina Bhutani
Headshot of Tina Bhutani
Tina Bhutani



The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Official Title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis


This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent subjects of age 12 years and above with moderate-to-severe AD. Eligible subjects must have a documented history of inadequate response to topical AD medication(s). Approximately 750 subjects will be randomized in 2:1 to receive either nemolizumab or placebo, stratified by baseline disease severity (Investigator's Global Assessment (IGA) = 3, moderate; IGA = 4, severe) and peak pruritus numeric rating scale (PP NRS) severity (PP NRS = 7; PP NRS < 7).


Moderate-to-Severe Atopic Dermatitis, CD14152, Nemolizumab, Atopic Dermatitis, Dermatitis, Atopic, Dermatitis, Eczema


You can join if…

Open to people ages 12 years and up

  • Male or female subjects aged ≥ 12 years at the screening visit Note: Enrollment of subjects aged 12 to 17 years has been opened after the IDMC has assessed interim safety data from the phase 2 study (Protocol 116912) and provided recommendations to the sponsor, who then determined the eligibility of this age group for enrollment in the study
  • Chronic AD that has been documented for at least 2 years
  • EASI score ≥ 16
  • IGA score ≥ 3
  • AD involvement ≥ 10% of BSA
  • PPNRS score of at least 4.0 at the screening and baseline visit
  • Documented recent history of inadequate response to topical medications (TCS with or without TCI)
  • Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection

You CAN'T join if...

  • Body weight < 30 kg
  • Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study
  • Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study
  • History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug excipients
  • Any clinically significant issue, based on investigator judgement


  • Galderma Investigational Site 8125
    San Francisco California 94115 United States
  • Galderma Investigational Site 8891
    North Hollywood California 91606 United States

Lead Scientist at UCSF

  • Tina Bhutani
    I am a dermatologist and clinical researcher in the Department of Dermatology at UCSF. I serve as co-director of the Psoriasis and Skin Treatment Center, a world-renowned clinic dedicated to the care of patients with psoriasis.


in progress, not accepting new patients
Start Date
Completion Date
Galderma R&D
Phase 3 Atopic Dermatitis (Eczema) Research Study
Study Type
Expecting 750 study participants
Last Updated